96 related articles for article (PubMed ID: 20632397)
21. GnRH agonists and antagonists decrease the metastatic progression of human prostate cancer cell lines by inhibiting the plasminogen activator system.
Dondi D; Festuccia C; Piccolella M; Bologna M; Motta M
Oncol Rep; 2006 Feb; 15(2):393-400. PubMed ID: 16391860
[TBL] [Abstract][Full Text] [Related]
22. Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas.
Clementi M; Sánchez C; Benitez DA; Contreras HR; Huidobro C; Cabezas J; Acevedo C; Castellón EA
Prostate; 2009 Jul; 69(10):1025-33. PubMed ID: 19301301
[TBL] [Abstract][Full Text] [Related]
23. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
Schubert A; Schulz H; Emons G; Gründker C
Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
[TBL] [Abstract][Full Text] [Related]
24. Structure, enzymatic stability and antitumor activity of sea lamprey GnRH-III and its dimer derivatives.
Mezo G; Czajlik A; Manea M; Jakab A; Farkas V; Majer Z; Vass E; Bodor A; Kapuvári B; Boldizsár M; Vincze B; Csuka O; Kovács M; Przybylski M; Perczel A; Hudecz F
Peptides; 2007 Apr; 28(4):806-20. PubMed ID: 17254668
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of gonadotropin-releasing hormone III analogs. Structure-antitumor activity relationships.
Mezö I; Lovas S; Pályi I; Vincze B; Kálnay A; Turi G; Vadász Z; Seprödi J; Idei M; Tóth G; Gulyás E; Otvös F; Mák M; Horváth JE; Teplán I; Murphy RF
J Med Chem; 1997 Oct; 40(21):3353-8. PubMed ID: 9341910
[TBL] [Abstract][Full Text] [Related]
26. Effect of the GnRH-agonist leuprolide on colonization of recipient testes by donor spermatogonial stem cells after transplantation in mice.
Dobrinski I; Ogawa T; Avarbock MR; Brinster RL
Tissue Cell; 2001 Apr; 33(2):200-7. PubMed ID: 11392673
[TBL] [Abstract][Full Text] [Related]
27. Gonadotropin-releasing hormone in apoptosis of prostate cancer cells.
Kraus S; Naor Z; Seger R
Cancer Lett; 2006 Mar; 234(2):109-23. PubMed ID: 16546667
[TBL] [Abstract][Full Text] [Related]
28. Effect of N-methyl substitution of the peptide bonds in luteinizing hormone-releasing hormone agonists.
Haviv F; Fitzpatrick TD; Swenson RE; Nichols CJ; Mort NA; Bush EN; Diaz G; Bammert G; Nguyen A; Rhutasel NS
J Med Chem; 1993 Feb; 36(3):363-9. PubMed ID: 8381183
[TBL] [Abstract][Full Text] [Related]
29. Role, mechanism of action and application of gonadoliberins in reproductive processes.
Teplán I
Acta Biol Hung; 1989; 40(1-2):3-36. PubMed ID: 2561244
[TBL] [Abstract][Full Text] [Related]
30. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
[TBL] [Abstract][Full Text] [Related]
31. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
Steinberg M
Clin Ther; 2009; 31 Pt 2():2312-31. PubMed ID: 20110043
[TBL] [Abstract][Full Text] [Related]
32. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
33. Design of biologically active, conformationally constrained GnRH antagonists.
Struthers RS; Tanaka G; Koerber SC; Solmajer T; Baniak EL; Gierasch LM; Vale W; Rivier J; Hagler AT
Proteins; 1990; 8(4):295-304. PubMed ID: 2091022
[TBL] [Abstract][Full Text] [Related]
34. Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor.
Maudsley S; Davidson L; Pawson AJ; Chan R; López de Maturana R; Millar RP
Cancer Res; 2004 Oct; 64(20):7533-44. PubMed ID: 15492280
[TBL] [Abstract][Full Text] [Related]
35. Solution structures of a 30-residue amino-terminal domain of the carp granulin-1 protein and its amino-terminally truncated 3-30 subfragment: implications for the conformational stability of the stack of two beta-hairpins.
Vranken WF; James S; Bennett HP; Ni F
Proteins; 2002 Apr; 47(1):14-24. PubMed ID: 11870861
[TBL] [Abstract][Full Text] [Related]
36. Degarelix 240/80 mg: a new treatment option for patients with advanced prostate cancer.
Boccon-Gibod L; Iversen P; Persson BE
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1737-43. PubMed ID: 19954284
[TBL] [Abstract][Full Text] [Related]
37. Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells.
Imai A; Takagi A; Horibe S; Takagi H; Tamaya T
Int J Oncol; 1998 Jul; 13(1):97-100. PubMed ID: 9625809
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a pituitary adenoma following a gonadotropin-releasing hormone agonist in a patient with prostate cancer.
Massoud W; Paparel P; Lopez JG; Perrin P; Daumont M; Ruffion A
Int J Urol; 2006 Mar; 13(3):303-4. PubMed ID: 16643633
[TBL] [Abstract][Full Text] [Related]
39. Gonadotropin‑releasing hormone inhibits the proliferation and motility of nasopharyngeal carcinoma cells.
Teng LH; Ahmad M; Ng WT; Sabaratnam S; Rasan MI; Parhar I; Khoo AS
Mol Med Rep; 2015 Oct; 12(4):4909-16. PubMed ID: 26151677
[TBL] [Abstract][Full Text] [Related]
40. Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4.
Manea M; Leurs U; Orbán E; Baranyai Z; Öhlschläger P; Marquardt A; Schulcz Á; Tejeda M; Kapuvári B; Tóvári J; Mezo G
Bioconjug Chem; 2011 Jul; 22(7):1320-9. PubMed ID: 21668011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
